Skip to content

Comparison of the effect of Vitagnus drops with metformin on the treatment of oligomenorrhea

Comparison of Vitagnus Vial with Metformin in Treatment of Oligomenorrhea: Randomized Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20181115041665N1
Enrollment
80
Registered
2018-11-27
Start date
2018-11-21
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oligomenorrhea. Secondary Oligomenorrhoea

Interventions

Intervention 1: Intervention group: From the first day of the menstrual cycle, 30 drops of vitagnus drops for 3 months in the morning, so that they will consume 3 weeks and discontinue one week. And t

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: The desire to participate in the study Conscientiousness Women aged 20-40 Oligomenorrhea: Delayedness from 40 days to 3 months Not having adrenal problems, thyroid and prolactin, cardiovascular diseases, diabetes, chronic diseases of the liver Non-pregnancy (negative pregnancy test) Non-lactation Not having known known uterus, ovaries and ... Not using concurrent hormonal treatments (chemical or herbal) BMI more than 18.5 kg / m²

Exclusion criteria

Exclusion criteria: Unwilling to continue participating in the study The diseases that Oraz continues to block the study Any abnormal anatomical condition or women's cancers Pregnancy and breastfeeding Receiving any hormonal medication (chemical or herbal) within the last 2 months Severe drug allergy or a history of unusual reactions to herbal medicines Need for other interventions Skinny people (BMI less than 18.5 kg / m²)

Design outcomes

Primary

MeasureTime frame
Menstrual start. Timepoint: Before the intervention, on the 1st, 2nd, and 3rd months, proceeded to work. Method of measurement: Question from the patient.;Bleeding time. Timepoint: Before the intervention, on the 1st, 2nd, and 3rd months, proceeded to. Method of measurement: Question from the patient.;The duration of each bleeding. Timepoint: Before the intervention, on the 1st, 2nd, and 3rd months, proceeded to. Method of measurement: Question from the patient.

Secondary

MeasureTime frame
Side effects. Timepoint: During the study. Method of measurement: question.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Momeninejad

Iran University of Medical Sciences

ma.momeninejad@gmail.com+98 21 5515 2192

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026